Lynx1 Capital Management LP Sells 213,025 Shares of Merus (NASDAQ:MRUS)

Lynx1 Capital Management LP decreased its position in shares of Merus (NASDAQ:MRUS - Free Report) by 11.9% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 1,580,841 shares of the biotechnology company's stock after selling 213,025 shares during the quarter. Merus makes up approximately 24.9% of Lynx1 Capital Management LP's holdings, making the stock its largest holding. Lynx1 Capital Management LP owned about 2.31% of Merus worth $66,474,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently bought and sold shares of MRUS. Tri Locum Partners LP increased its holdings in Merus by 80.7% in the fourth quarter. Tri Locum Partners LP now owns 347,303 shares of the biotechnology company's stock valued at $14,604,000 after purchasing an additional 155,146 shares during the last quarter. Boothbay Fund Management LLC bought a new stake in shares of Merus in the 4th quarter valued at about $3,364,000. Susquehanna Fundamental Investments LLC acquired a new stake in shares of Merus in the 4th quarter valued at approximately $2,268,000. Nebula Research & Development LLC boosted its stake in Merus by 4.9% during the 4th quarter. Nebula Research & Development LLC now owns 31,485 shares of the biotechnology company's stock worth $1,324,000 after acquiring an additional 1,482 shares during the last quarter. Finally, Voya Investment Management LLC boosted its stake in Merus by 5.8% during the 4th quarter. Voya Investment Management LLC now owns 62,000 shares of the biotechnology company's stock worth $2,607,000 after acquiring an additional 3,405 shares during the last quarter. 96.14% of the stock is currently owned by institutional investors.

Merus Stock Performance

MRUS traded down $0.06 on Thursday, hitting $45.45. 766,212 shares of the company were exchanged, compared to its average volume of 710,714. The company has a market cap of $3.14 billion, a PE ratio of -11.51 and a beta of 1.02. Merus has a 12 month low of $33.19 and a 12 month high of $61.61. The stock's fifty day moving average is $44.03 and its 200-day moving average is $44.62.

Merus (NASDAQ:MRUS - Get Free Report) last issued its earnings results on Thursday, February 27th. The biotechnology company reported ($0.41) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.89) by $0.48. Merus had a negative net margin of 680.61% and a negative return on equity of 38.89%. The company had revenue of $9.14 million for the quarter, compared to analysts' expectations of $10.57 million. As a group, equities research analysts expect that Merus will post -3.85 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on MRUS shares. Piper Sandler started coverage on shares of Merus in a report on Thursday, February 13th. They issued an "overweight" rating and a $84.00 target price on the stock. Wells Fargo & Company assumed coverage on Merus in a report on Friday, February 7th. They set an "overweight" rating and a $91.00 target price on the stock. HC Wainwright reaffirmed a "buy" rating and set a $85.00 price target on shares of Merus in a research report on Monday, March 3rd. Needham & Company LLC reiterated a "buy" rating and issued a $83.00 price objective on shares of Merus in a research report on Wednesday, April 9th. Finally, William Blair restated an "outperform" rating on shares of Merus in a report on Monday. One investment analyst has rated the stock with a sell rating, fourteen have issued a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Buy" and an average price target of $85.31.

Merus Company Profile

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.